Barinthus Biotherapeutics (BRNS) Receivables - Other (2020 - 2026)

Barinthus Biotherapeutics has reported Receivables - Other for 7 years, with the latest figure at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other fell 58.89% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (down 58.89% YoY), and the FY2025 full-year result was $1.1 million, down 84.48% from the prior year.
• Receivables - Other for Q1 2026 stood at $1.2 million, up from $1.1 million in the prior quarter.
• The five-year high for Receivables - Other was $7.1 million in Q4 2024, with the low at $143000.0 in Q2 2022.
• Historically, Receivables - Other has averaged $3.6 million across 5 years, with a median of $4.5 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables - Other sank 96.86% — and 2024, when it jumped 1407.67%.
• Barinthus Biotherapeutics' Receivables - Other stood at $4.5 million in 2022, then rose by 8.08% to $4.9 million in 2023, then jumped by 45.46% to $7.1 million in 2024, then plunged by 84.48% to $1.1 million in 2025, then climbed by 11.19% to $1.2 million in 2026.
• The last three Receivables - Other figures came in at $1.2 million (Q1 2026), $1.1 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.